Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Atezolizumab and Tiragolumab for the Treatment of Patients with Refractory Locally Advanced, Metastatic or Recurrent Cancer of Unknown Primary

Trial Status: active

This phase II trial tests how well atezolizumab and tiragolumab works in treating patients with cancer of unknown primary that has not responded to previous treatment (refractory) and that has spread to nearby tissue or lymph nodes (locally advanced), that has spread from where it first started (primary site) to other places in the body (metastatic) or that has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tiragolumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving atezolizumab and tiragolumab may be effective in treating patients with refractory, locally advanced, metastatic or recurrent cancer of unknown primary.